Drug class
Reverse Transcriptase Inhibitors clinical trials
A class of medicines: the studies that test any of its 30 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones.
Keep track of what changes. Save the reverse transcriptase inhibitors studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesMedicines in this class
Studies that test each. A study of two counts under both, and once above.
- Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
- 112
- Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
- 11
- Lamivudine, zidovudine drug combination
- 8
- Emtricitabine, Rilpivirine, Tenofovir Drug Combination
- 7
- Stavudine, lamivudine, nevirapine drug combination
- 3
- Emivirine
- 1
Studies by the year they started
1,018 studies that test it; most in 2015 (76); 1 more planned to start later
| Year | Studies |
|---|---|
| 1990 | 2 |
| 1991 | 1 |
| 1992 | 1 |
| 1993 | 1 |
| 1994 | 1 |
| 1995 | 2 |
| 1996 | 2 |
| 1997 | 6 |
| 1998 | 3 |
| 1999 | 29 |
| 2000 | 14 |
| 2001 | 18 |
| 2002 | 21 |
| 2003 | 20 |
| 2004 | 45 |
| 2005 | 47 |
| 2006 | 53 |
| 2007 | 41 |
| 2008 | 54 |
| 2009 | 52 |
| 2010 | 37 |
| 2011 | 55 |
| 2012 | 59 |
| 2013 | 33 |
| 2014 | 37 |
| 2015 | 76 |
| 2016 | 34 |
| 2017 | 38 |
| 2018 | 37 |
| 2019 | 34 |
| 2020 | 38 |
| 2021 | 28 |
| 2022 | 20 |
| 2023 | 21 |
| 2024 | 24 |
| 2025 | 19 |
| 2026 | 15 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 549 · Other 779
National Institute of Allergy and Infectious Diseases (NIAID) (216) · Gilead Sciences (103) · Merck Sharp & Dohme LLC (52) · Glaxo Wellcome (41) · Bristol-Myers Squibb (40) · ViiV Healthcare (38) · Boehringer Ingelheim (32) · Tibotec Pharmaceuticals, Ireland (27)
Studies
Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten.
Testing one of them · 1,328
- Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)RecruitingPhase 2National Cancer Institute (NCI)NCT01419561Written as Zidovudine
- Reverse Triple Negative Immune Resistant Breast CancerRecruitingPhase 2Fudan UniversityNCT05076682Written as Efavirenz
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV TreatmentsRecruitingPhase 4Gilead SciencesNCT06337032Written as F/TAF (High Dose Tablet)
- A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1RecruitingPhase 2Gilead SciencesNCT07645287Written as B/F/TAF
- A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)RecruitingPhase 2/3Merck Sharp & Dohme LLCNCT07266831Written as ISL
- Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 TreatmentRecruitingPhase 2/3Gilead SciencesNCT07708727Written as B/F/TAF
- DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kgNot yet recruitingPhase 2Merck Sharp & Dohme LLCNCT07862569Written as DOR/ISL
- Sleep Outcomes and Multidimensional Sleep Assessment - a Randomized Trial of Dolutegravir- vs Doravirine-based Antiretroviral Therapy in People Living With HIVNot yet recruitingPhase 4University of Witwatersrand, South AfricaNCT07673965Written as Tenofovir disoproxil fumarate 300mg / Lamivudine 300mg / Doravirine 100mg
- Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized StudyRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT05652478Written as Tenofovir Disoproxil Fumarate
- Efficacy and Safety of Doravirine in the Rapid InitiationRecruitingPhase 4Fundación HuéspedNCT07357584Written as Doravirine / lamivudine/ Tenofovir Disoproxil Oral Tablet
- A Study of Ulonivirine (MK-8507) and Methadone in Healthy Volunteers (MK-8507-019)RecruitingPhase 1Merck Sharp & Dohme LLCNCT07595263Written as Ulonivirine
- Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV RemissionRecruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT02140255Written as Nevirapine (NVP)
- Efavirenz for the Treatment of Creutzfeldt-Jakob DiseaseRecruitingPhase 3Xuanwu Hospital, BeijingNCT07482085Written as Efavirenz
- REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidERecruitingPhase 4CAN Community HealthNCT07476339Written as Bictegravir, emtricitabine, and tenofovir alafenamide
- Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF/FTC in MSM in Thailand and France.RecruitingPhase 3ANRS, Emerging Infectious DiseasesNCT05813964Written as TAF/FTC 25mg/200mg fixed-dose combination tablets
- An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in AfricaNot yet recruitingPhase 3University College, LondonNCT07792096Written as Abacavir (ABC)
- A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV TreatmentRecruitingPhase 3ViiV HealthcareNCT07393659Written as Dolutegravir (DTG)/ Lamivudine (3TC)
- DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 InfectionRecruitingPhase 3ANRS, Emerging Infectious DiseasesNCT06203132Written as Doravirine + tenofovir DF + lamivudine
- Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014)Not yet recruitingPhase 1Merck Sharp & Dohme LLCNCT05093972Written as Ulonivirine
- Effects of Antiviral Therapies on Epstein-Barr Virus ReplicationEnrolling by invitationPhase 2Massachusetts General HospitalNCT05957913Written as Truvada (tenofovir/emtricitabine)
See all 1,328 studies that test one of the reverse transcriptase inhibitors →